Publications

Nature communications

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

24-06-2026

Cancer treatment reviews

Progress toward personalized management of stage II/III triple negative breast cancer.

01-06-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity.

01-06-2026

Genome medicine

The contribution of rare germline variants to the immune landscape of breast cancer.

09-05-2026

Breast cancer research and treatment

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

05-05-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

21-04-2026

Clinical breast cancer

Long-Term Health Issues of Adolescent and Young Adult Breast Cancer Survivors.

01-03-2026

Nature cancer

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

01-03-2026

JAMA oncology

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

01-02-2026

Cell reports. Medicine

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

16-12-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial.

15-12-2025

ESMO open

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

01-12-2025

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.

01-12-2025

The Lancet. Digital health

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

01-11-2025

Cancer treatment reviews

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

01-11-2025

Psycho-oncology

Health-Related Quality of Life in Adolescents and Young Adults With an Uncertain or Poor Cancer Prognosis: Quantitative Baseline Results of the CORD-AYA Study.

01-11-2025

Nature methods

Automated classification of cellular expression in multiplexed imaging data with Nimbus.

01-10-2025

Immuno-oncology technology

Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.

01-09-2025

Immuno-oncology technology

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

01-09-2025

EClinicalMedicine

Exploring personalized neoadjuvant therapy selection strategies in breast cancer: an explainable multi-modal response model.

01-08-2025

Cancer cell

Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread.

14-07-2025

Journal for immunotherapy of cancer

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.

25-06-2025

Journal of the National Cancer Center

Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype.

01-06-2025

Nature cancer

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.

01-06-2025

Nature medicine

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

01-02-2025

Breast cancer research and treatment

Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

01-02-2025

bioRxiv : the preprint server for biology

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

28-01-2025

NPJ breast cancer

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.

23-01-2025

Nature

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

01-01-2025

Key Publication

Cancer discovery

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

02-12-2024

Breast (Edinburgh, Scotland)

Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy.

01-12-2024

Nature communications

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

07-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

20-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

JAMA oncology

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

01-08-2024

bioRxiv : the preprint server for biology

Automated classification of cellular expression in multiplexed imaging data with Nimbus.

03-06-2024

Breast (Edinburgh, Scotland)

Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.

01-06-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?

01-05-2024

JAMA

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

02-04-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

Cancers

The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([⁶⁸Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study.

28-02-2024

BMC medicine

Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

09-01-2024

Immunity

Chi3l1: New kid on the T cell blockade.

12-12-2023

Seminars in oncology

Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.

01-12-2023

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosis.

27-11-2023

Journal for immunotherapy of cancer

Quantifying the impact of immunotherapy on RNA dynamics in cancer.

01-11-2023

Breast cancer research : BCR

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

04-10-2023

Breast (Edinburgh, Scotland)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

01-08-2023

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Progress toward personalized management of stage II/III triple negative breast cancer.

Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity.

The contribution of rare germline variants to the immune landscape of breast cancer.

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Long-Term Health Issues of Adolescent and Young Adult Breast Cancer Survivors.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial.

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

Health-Related Quality of Life in Adolescents and Young Adults With an Uncertain or Poor Cancer Prognosis: Quantitative Baseline Results of the CORD-AYA Study.

Automated classification of cellular expression in multiplexed imaging data with Nimbus.

Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Exploring personalized neoadjuvant therapy selection strategies in breast cancer: an explainable multi-modal response model.

Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread.

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.

Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype.

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy.

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

Automated classification of cellular expression in multiplexed imaging data with Nimbus.

Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.

Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([68Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study.

Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

Chi3l1: New kid on the T cell blockade.

Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.

A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosis.

Quantifying the impact of immunotherapy on RNA dynamics in cancer.

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

This site uses cookies

The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([⁶⁸Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study.